Search for Clinical Trial Results

Sponsored By

Anaplastic Large Cell Lymphoma - 61 Studies Found

Status Study
Completed Study Name: Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma
Condition: Large Cell Lymphoma
Date: 2004-12-10
Interventions: Drug: SGN-30
Completed Study Name: Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas
Condition: Anaplastic Large Cell Lymphoma, ALK-Positive
Date: 2015-04-03
Interventions: Drug: crizotinib
Withdrawn Study Name: MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma
Condition: Lymphoma, Large-Cell
Date: 2006-03-01
Interventions: Drug: MDX-060
Active, not recruiting Study Name: Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Condition:
  • Brain and Central Nervous System Tumors
  • Lymphoma
  • Neuroblas
    Date: 2009-07-14
    Interventions:
    • Drug: crizotinib
    • Other: pharmacogenomic st
Completed Study Name: A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma
Condition:
  • Lymphoma, Large-Cell, Anaplastic
  • Lymphoma, Non-Hodgkin

Date: 2009-03-19
Interventions: Drug: brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion
Completed Study Name: Monoclonal Antibody Therapy in Treating Patients With Refractory Anaplastic Large Cell Lymphoma or Hodgkin's Lymphoma
Condition: Lymphoma
Date: 1999-11-01
Interventions: Biological: monoclonal antibody HeFi-1
Recruiting Study Name: AT13387 in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-cell Lymphoma
Condition:
  • ALK Positive
  • BCL6 Positive
  • Recurrent Date: 2015-10-08
    Interventions:
    • Other: Laboratory Biomarker Analysis

Active, not recruiting Study Name: ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas
Condition:
  • Anaplastic Large-Cell Lymphoma
  • Non-Hodgkin Lymphoma
  • Date: 2013-01-23
    Interventions:
    • Drug: brentuximab vedotin 1.8

Recruiting Study Name: Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)
Condition: Lymphoma
Date: 2014-06-11
Interventions: Drug: Brentuximab Vedotin Starting dose: 1.2 mg/kg by vein on Day 1 for the first 2, 21 day cycles. Dose
Completed Study Name: Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas
Condition: Non-Hodgkin Lymphoma
Date: 2014-10-05
Interventions: Drug: Brentuximab vedotin Brentuximab vedotin must not be administered as an IV push or bolus. It must b
<<< Previous | Next >>>